N itroglycerin (NTG) remains one of the foremost drugs in the treatment of acute and chronic coronary syndromes. Despite its beneficial effects on angina threshold in patients with coronary artery disease, its efficacy during continuous treatment is limited because of the rapid development of nitrate tolerance. 1, 2 Animal as well as clinical studies have also demonstrated negative effects of NTG treatment for vascular function as indicated by the development of crosstolerance to endothelium-dependent vasodilators such as acetylcholine (ACh) 3, 4 and calcium ionophore. 5 The most attractive hypotheses so far to explain the phenomenon of cross-tolerance include a desensitization of the target enzyme guanylyl cyclase 5 and/or increased vascular production of reactive oxygen species leading to enhanced breakdown of endothelial-derived nitric oxide (NO). 4 It remains to be established, however, whether in vivo supplementation with NTG alters gene expression of endothelial nitric oxide synthase (NOS III). Nitrovasodilator therapy with the sydnonimine CAS 936 has been shown to result in a more than 50% reduction in the expression of NOS III gene. 6 In addition, exogenously applied NO has been demonstrated to directly inhibit NOS III activity. 7 More recent in vitro experiments revealed that the expression of the NOS III gene is protein kinase C (PKC) dependent. 8 Two studies demonstrated an activation of PKC in the setting of nitrate tolerance. 9,10 NTG treatment for 3 days resulted in an increase in hypersensitivity to vasoconstrictors such as angiotensin II, phenylephrine, and serotonin, a phenomenon that was blocked ex vivo with PKC inhibitors such as staurosporine and calphostin C. 10 In in vivo studies, PKC inhibitors prevented enhanced sensitivity to vasoconstrictors such as phenylephrine and thromboxane as well as the development of nitrate tolerance. 9 Interestingly, recent studies demonstrate that NO can directly activate PKC isoforms in the heart. The authors speculated that these findings may have implications for long-term nitrate therapy. 11 On the basis of these considerations, we investigated to what extent long-term treatment with NTG alters the expression and function of the NOS III gene. We also tested with electron spin resonance (ESR) spectroscopy to what extent long-term NTG treatment may influence the bioavailability of NO in vascular tissue.
Materials and Methods
The present study was undertaken in accordance with the guidelines for animal experimentation at University Hospital Eppendorf, Hamburg, Germany.
Animal Model: In Vivo Nitrate Tolerance
Wistar rats (210 to 250 g; Harlan, Horst, Netherlands) were treated with a subcutaneous osmotic minipump (Alza Corp) filled with either NTG or vehicle. NTG infusion rate averaged 0.5 mg/h.
Organ Chamber Experiments
Vasodilator responses to NTG and the endothelium-dependent vasodilator ACh were determined in organ chambers as described recently. 12 To address the role of PKC in mediating nitrate tolerance, aortic rings from control and nitrate-tolerant animals were incubated with the specific PKC inhibitors chelerythrine (3 mol/L) and Gö 6976 (1 mol/L) for 30 minutes. 13 To address a role of intracellular L-arginine depletion in nitrate tolerance and cross-tolerance to ACh, aortic rings from NTG-treated rats were incubated with L-arginine (10 Ϫ3 mol/L for 30 minutes).
Measurement of O 2 ⅐؊ Production in Intact Vessels With Lucigenin-and Cypridina Luciferin Analog-Enhanced Chemiluminescence
⅐Ϫ production in intact vessels was measured as lucigenin-derived chemiluminescence (LDCL) or using a Cypridina luciferin analog (CLA) as described previously. 14, 15 In separate studies, the effects of PKC inhibition with chelerythrine (3 mol/L) and Gö 6976 (1 mol/L for 30 minutes) on vascular O 2 ⅐Ϫ production were tested. To address the influence of endothelial (NOS III derived) NO on vascular LDCL, the endothelium was mechanically removed or vessels were incubated with N G -nitro-L-arginine (L-NNA, 1 mmol/L). 14 To estimate stimulated NOS III-mediated O 2 ⅐Ϫ production by aortic tissue from control and tolerant animals, calcium ionophore A23187 (10 mol/L) was added to the tissue as described. 16 
ESR Studies: Detection of Vascular NO and O 2

⅐؊
Concentrations of NO in rat aorta in the presence of O 2 ⅐Ϫ were assayed using ESR spectroscopy and the spin-trap iron (II)-prolinedithio-carbamate [Fe(PrTC) 2 ], which has been shown to trap NO with high efficacy by forming an ESR-detectable paramagnetic complex Fe(NO)(PrTC) 2 . 17 ESR measurements with vascular samples were performed with an X-band ESR spectrometer (ECS 106, Bruker, Karlsruhe, Germany) and a flat quartz cell (Bruker, ERC 4201) placed into a dual-probe ESR resonator (ER 4105 DR, Bruker, Germany).
To quantify O 2 ⅐Ϫ in vessels from animals with and without NTG treatment, the formation of CP°radicals was monitored using ESR spectroscopy and 1-hydroxy-3-carboxy-2,2,5,-tetramethylpyrrolidine hydrochloride (CPH, 1 mmol/L) as described. 15 
Cloning of a Rat NOS III cDNA Fragment and RNase Protection Analysis
A cDNA fragment of rat NOS III was generated with reverse transcription-polymerase chain reaction as described 18 using 2 g of total RNA from rat aorta. Oligonucleotide primers were GACATT-GAGAGCAAAGGGCTGC (sense) and CGGCTTGTCACCTC-CTGG (antisense). The cloning of the rat ␥-actin probe (used for normalization of the RNase protection assays) was done as previously described. 19 RNase protection assays were performed with a mixture of RNase A and RNase T1 as described. 8, 18 The protected RNA fragments of NOS III and ␥-actin were 425 nt and 110 nt, respectively.
Superoxide Dismutase Activity Assay
To address the effects of PKC inhibition on vascular superoxide dismutase (SOD) activity, SOD activity was assessed by measuring the rate of SOD-sensitive autooxidation of 6-hydroxydopamine as described. 20 
Western Blot Analyses
Rat aortic tissue was homogenized and subjected to SDS-PAGE and subsequently blotted to nitrocellulose membranes (BioRad). The blots were developed with a mouse monoclonal antibody to human NOS III (dilution 1:2500, Transduction Laboratories). The 135-kDa NOS III band was quantified by densitometry.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
Effects of In Vivo NTG Treatment on NTG-and ACh-Induced Vasorelaxation
Three days of treatment with NTG markedly attenuated the NTG concentration-response relationship (Table) . Removal of the endothelium produced a shift to the left of the control curve and increased the maximum relaxing effect of NTG in control and nitrate-tolerant aortas. Tolerance was associated with cross-tolerance to the endothelium-dependent vasodilator ACh. Incubation of tolerant tissue with chelerythrine and Gö 6976 significantly improved NTG-induced vasodilation in tolerant tissue while having no significant effects on the NTG concentration-response relationship in control vessels (Table). Incubation of tolerant tissue with L-arginine did not modify the ACh dose-response relationship (ED 50 tol: 7.22Ϯ0.09 versus 6.94Ϯ0.11 [nϭ10]; max.relax tol: 68Ϯ6% versus 70Ϯ5 with L-arginine, respectively).
Effects of PKC Inhibition With Chelerythrine and Gö 6976 on the NTG Concentration-Response Relationship in Control and Nitrate-Tolerant Rat Aorta
Effects of In Vivo NTG Treatment on Vascular O 2
⅐؊ Production Determined With LDCL, CLA Chemiluminescence, and ESR Spectroscopy
In control vessels with intact endothelium, LDCL values averaged 1355Ϯ123 counts/mg tissue per minute (nϭ8, Figure 1 ). NTG treatment for 3 days markedly increased vascular O 2 ⅐Ϫ production in these vessels to 3334Ϯ414 counts/mg per minute (Figure 1 (Figure 1 ). In vessels from NTGtreated rats, LDCL was significantly decreased in response to L-NNA, indicating a marked contribution of NOS III to the O 2 ⅐Ϫ production in tolerant vessels. There were no significant differences in the LDCL signal in vessels without endothelium (control: 3132Ϯ184 versus tolerant: 2799Ϯ335 counts/mg per minute). Incubation of tolerant tissue with the NOS III substrate L-arginine did not significantly modify vascular steady-state O 2 ⅐Ϫ levels (tolerant 3388Ϯ124 versus 3028Ϯ33 counts/mg per minute, nϭ8 each).
Incubation of endothelium-intact control vessels with the PKC inhibitors chelerythrine or Gö 6976 had no significant effects on LDCL signals from control vessels. However, the two PKC inhibitors markedly inhibited LDCL in vessels from NTG-treated animals ( Figure 1) .
Calcium ionophore A23187 has been shown to stimulate the activity of the calcium-dependent NOS III. 16 This usually results in an increased NO generation. In a situation of enzymatic uncoupling, however, O 2 ⅐Ϫ production can also increase. 16 Indeed, in control vessels, A23187 slightly, but significantly, increased LDCL. In tolerant tissue, the A23187-induced increase in O 2 ⅐Ϫ was markedly increased (Figure 2 ). Incubation of control tissue and tolerant tissue with the PKC inhibitor chelerythrine significantly inhibited NOS III-mediated O 2 ⅐Ϫ production ( Figure 2) . Likewise, endothelial removal resulted in an inhibition of the A23187-mediated increase in LDCL (Figure 2 ).
Effects of In Vivo Treatment With NTG on NOS III mRNA Expression and NOS III Protein
As shown in Figure 3 , NTG treatment for 3 days increased NOS III mRNA expression to 236Ϯ28% of control (100%). Western blot analyses with protein from rat aortas revealed a comparable increase (Figure 4 ). Densitometric analyses of the NOS III protein bands indicated an increase to 239Ϯ17% after NTG treatment.
Effects of In Vivo NTG Treatment on Vascular NO Bioavailability Determined With ESR Spectroscopy
The effects of NTG treatment on vascular NO bioavailability in vascular tissue as assessed with ESR spectroscopy are depicted in Figure 5 . The representative ESR recording of the signal of the iron-nitrosyl-dithiocarbamate complex Fe(NO) Effects of NTG treatment on stimulated NOS III-mediated O 2 ⅐Ϫ production stimulated with calcium ionophore (A23187). NTG treatment for 3 days markedly increased calcium ionophore-stimulated NOS III-mediated O 2 ⅐Ϫ production, which was strikingly inhibited by pretreating vessels with the PKC inhibitor chelerythrine and by removing the endothelium. Data are presented as A23187-induced increases in LDCL (delta counts/ milligram per minute; meanϮSEM from 4 to 8 experiments). *PϽ0.05 vs control with endothelium; †PϽ0.05 vs control and tolerant with endothelium.
(PrTC) 2 was strikingly reduced in vessels from NTG-treated animals compared with spectra obtained with vessels from control animals. This indicates a marked reduction of NO bioavailability in tolerant tissue.
Effects of PKC Inhibition on Vascular SOD Activity
In control vessels, SOD activity averaged 8.69Ϯ0.5 U/mg protein (nϭ4). PKC inhibition with chelerythrine and Gö 6976 did not modify vascular SOD activity (8.74Ϯ0.68 and 7.97Ϯ0.25 U/mg protein, nϭ4 each).
Discussion
The results of the present study show that in vivo treatment with NTG for 3 days leads to nitrate tolerance and crosstolerance to the endothelium-dependent vasodilator ACh. Interestingly, tolerance and endothelial dysfunction were associated with a doubling in NOS III mRNA and protein.
Studies with the NOS III stimulator A23187 and the inhibitor of NOS III activity L-NNA identified the enzyme as a significant source of O 2 ⅐Ϫ in the setting of tolerance. The PKC inhibitors chelerythrine and Gö 6976 markedly reduced vascular O 2 ⅐Ϫ production and improved NTG-induced vascular relaxations in the aortas of nitrate-tolerant rats. This suggests an important role for PKC in mediating nitrate tolerance.
Role for Oxidative Stress in Nitrate Tolerance
The present study demonstrates in agreement with previous observations that long-term nitrate treatment leads to nitrate tolerance associated with increases in endothelial O 2 ⅐Ϫ and cross-tolerance to endothelium-dependent vasodilators such as ACh. 4 As a potential O 2 ⅐Ϫ source, we identified a vascular, angiotensin II-sensitive NAD(P)H oxidase, 12 a significant O 2 ⅐Ϫ source in endothelial 21 and smooth muscle cells. 22 The concept of increased oxidative stress as a consequence of long-term NTG therapy was further corroborated by studies demonstrating that in vivo, but not in vitro, treatment with NTG decreases total vascular SOD activity and expression of the vascular Cu/Zn SOD. 20 These observations led us to conclude that increased endothelial O 2 ⅐Ϫ formation rather than desensitization of the smooth muscle guanylyl cyclase is a decisive determinant of in vivo nitrate tolerance. 4 This concept was further supported by clinical observations demonstrating that antioxidants are able to reverse or to prevent the development of nitrate tolerance in patients with stable coronary artery disease and heart failure. 23, 24 The present study goes along with the oxidative stress concept of nitrate tolerance. Using a different animal model, we found that infusion of NTG for 3 days caused a marked increase in vascular O 2 ⅐Ϫ as demonstrated with LDCL-or CLA-derived chemiluminescence as well as with ESR spectroscopy. As before, we found that removal of the endothelium significantly improved relaxations to NTG 4, 25 in tissue from nitrate-tolerant animals. 
NTG Treatment and NOS III Expression
In the present study, we found a marked increase in the expression of the NOS III mRNA and protein in response to a 3-day NTG treatment. This observation is somewhat surprising because previous studies demonstrated a decreased rather than increased expression of the NOS III gene in response to long-term treatment with nitrovasodilators. 26 There is also evidence that supplementation of vascular tissue, endothelial cells, or platelets with high concentrations of NO inhibits NOS III activity. 7 Recent studies extended these observations by demonstrating that sodium nitroprusside (SNP) treatment had no effect on NOS III mRNA or protein levels in cultured pulmonary arterial endothelial cells but did produce a significant decrease in enzyme activity. 27 Similarly, Chen and Mehta 28 described a decrease in NOS III activity in washed human platelets on exposure to NTG but failed to detect changes in NOS III mRNA.
The mechanisms underlying increased expression of NOS III in the present study in response to long-term NTG treatment remain unclear. Li et al 8 have recently demonstrated increased expression of NOS III in endothelial cells after PKC activation. Interestingly, other studies have shown that long-term NTG treatment leads to PKC activation in vascular tissue. 9, 10 In Nitrate-Tolerant Vessels, NOS III Is Involved in O 2 ⅐؊ Production, and This Process Is PKC Dependent
With the present studies, we can demonstrate cross-tolerance to the endothelium-dependent vasodilator ACh and with ESR studies, a marked reduction in vascular NO bioavailability, despite increased NOS III expression. We also provide evidence that an uncoupled NOS III is-at least partially-involved in the increased O 2 ⅐Ϫ production seen after in vivo treatment with NTG. When aortas of untreated animals were exposed to the NOS inhibitor L-NNA, we established a significant increase in the LDCL signal. This indicates that the amount of NO formed in normal vascular endothelium under basal conditions is sufficiently high to compete for the reaction of O 2 ⅐Ϫ with LDCL. 14 In contrast, incubation of tolerant tissue with L-NNA decreased rather than increased steady-state vascular O 2 ⅐Ϫ levels, identifying NOS III as a significant O 2 ⅐Ϫ source. As an additional tool to demonstrate uncoupling of NOS III, we used A23187. Recent studies have demonstrated that A23187 stimulates the simultaneous release of NO as well as O 2 ⅐Ϫ and that A23187-induced O 2 ⅐Ϫ was significantly higher in aortas from prehypertensive spontaneously hypertensive rats compared with increases in O 2 ⅐Ϫ in control vessels 16 compatible with an uncoupling of NOS III. Similarly, we found that A23187-induced increases in LDCL were markedly stronger in nitrate-tolerant than in control aortas. As before, 16 the A23187-induced increase in LDCL was almost completely inhibited by preincubation of vascular tissue from control and tolerant animals with the NOS inhibitor L-NNA indicating that the observed increases in LDCL were unlikely due to activation of non-NOS O 2 ⅐Ϫ sources. The observed inhibitory effect of L-NNA on A23187 responses is in line with previous in vitro studies in which N G -nitro-L-arginine methyl ester (L-NAME) inhibited NOS III-mediated O 2 ⅐Ϫ production in endothelial cells treated with LDL 29 and is also in agreement with more recent studies showing that L-NAME and L-NNA have inhibitory effects on O 2 ⅐Ϫ production of NOS I 30 and NOS III 31 in an uncoupled state.
For isolated NOS enzymes, two major conditions have been described that favor O 2 ⅐Ϫ production, namely BH4 as well as L-arginine deficiency. 31, 32 However, in intact cells, a severe L-arginine and BH4 deficiency is not very likely to occur. In addition, in the present experiments, we can demonstrate that L-arginine is not able to improve cross-tolerance to the endothelium-dependent vasodilator ACh and does not reduce vascular O 2 ⅐Ϫ production of tolerant tissue significantly. These observations make it very unlikely that uncoupling of NOS III due to intracellular L-arginine depletion accounts for the cross-tolerance phenomenon. Therefore, other mechanisms have to be postulated. Because PKC inhibition with chelerythrine and Gö 6976 was able to inhibit O 2 ⅐Ϫ production of tolerant tissue as well as A23187-stimulated NOS III-mediated O 2 ⅐Ϫ production, one possible explanation is the phosphorylation of NOS III (or an NOS III-associated protein) by PKC. Indeed, NOS III has been shown to be a phosphorylation target of PKC, 33 and PKC activation has been shown to increase vascular O 2 ⅐Ϫ production. 34 
Mechanisms of PKC Activation During NTG Treatment
The mechanisms underlying PKC activation during NTG therapy are not known at this time. NTG therapy has been shown to increase circulating angiotensin II levels, 1 which in turn may activate PKC, ultimately leading to the activation of the NAD(P)H oxidase and increased vascular O 2 ⅐Ϫ production. 35 11, 38 or via stimulation of phospholipase D. 39, 40 Interestingly, NO-induced O 2 ⅐Ϫ production has been shown to be associated with a PKC-dependent NOS III phosphorylation. 27 On the basis of these observations, it is tempting to speculate that long-term in vivo therapy with NTG may lead directly (NO mediated) or indirectly (via angiotensin II) to PKC activation within endothelial cells, which in turn may be also be responsible for the observed increases in NOS III expression. 8 Taken together, these data suggest that long-term NTG treatment causes not only an expressional upregulation but also an uncoupling of the endothelial NOS III gene, resulting in an increased basal and stimulated NOS III-mediated O 2 ⅐Ϫ production. This may explain why in vivo treatment with NTG has been shown to cause cross-tolerance to endothelium-dependent vasodilators such as Ach. 4, 5 In addition, the striking in vitro effects of PKC inhibitors on in vivo tolerance and NOS III-mediated O 2 ⅐Ϫ production point to a causal role for PKC in mediating these phenomena and also suggest a therapeutic potential of this class of drugs in preventing the development of nitrate tolerance.
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